FDA Approves ASCENIV(formerly referred to as RI-002), A Novel Intravenous Immune Globulin

See the Press Release

Innovation for the immunocompromised

Our goal is to be a leader in developing and commercializing specialized, targeted, plasma-derived therapeutics to extend and enhance the lives of individuals who are naturally or medically immunocompromised.